Prosecution Insights
Prosecution Insights
38 pending office actions • 24 art units • 35 examiners • 0 of 38 (0%) have an AI response strategy ready • 51 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 6 (16%) |
| §103 only | 9 (24%) |
| §102 only | 3 (8%) |
| §112 only | 3 (8%) |
| Double-patenting only | 1 (3%) |
| Double-patenting + other | 5 (13%) |
| Multi-statute (no §101) | 11 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 2 | 42.0% | +58.8% |
| DIBRINO, MARIANNE | 2 | 43.2% | +41.6% |
| MOSELEY II, NELSON B | 2 | 67.8% | +41.6% |
| DHAR, MATASHA | 1 | 43.8% | +47.5% |
| PAPCIAK, SHARON M | 1 | 49.5% | +22.5% |
| JOHANSEN, PETER N. | 1 | 58.9% | +24.3% |
| DUNN, LINDSAY MICHELLE | 1 | 100.0% | +0.0% |
| ZHU, JIANJIAN | 1 | 61.0% | +83.7% |
| BURKHART, MICHAEL D | 1 | 62.2% | +11.5% |
| JOHNSON, ALLISON MARIE | 1 | 45.0% | +49.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18368647 | METHODS OF PERSONALIZED PRECONDITIONING FOR CELL THERAPY | DUNN, LINDSAY MICHELLE | 26d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17697028 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS | VIJAYARAGHAVAN, JAGAMYA NMN | 91d overdue |
| 17047621 | SYSTEMS AND METHODS FOR DETECTING CANCER VIA cfDNA SCREENING | CHUNDURU, SURYAPRABHA | 17d overdue |
| 16990185 | NON-HLA RESTRICTED T CELL RECEPTORS AND USES THEREOF | RIGA, MICHAEL ANGELO | 4d overdue |
| 17914731 | SYSTEMS AND METHODS FOR DISTINGUISHING PATHOLOGICAL MUTATIONS FROM CLONAL HEMATOPOIETIC MUTATIONS IN PLASMA CELL-FREE DNA BY FRAGMENT SIZE ANALYSIS | BAILEY, STEVEN WILLIAM | 15d |
| 17890694 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK OF POOR CANCER SURVIVAL | BUCHANAN, BAILEY CHEYENNE | 34d |
| 17681113 | METHODS OF GENERATING AND ISOLATING MIDBRAIN DOPAMINE NEURONS | TRAN, KHOA NHAT | — |
| 17526812 | MESOTHELIN CARS AND USES THEREOF | DIBRINO, MARIANNE | — |
| 17319495 | STEM CELL-BASED MULTIPLEX METHODS AND COMPOSITIONS | TRAN, KHOA NHAT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18606866 | INTESTINAL MICROBIOTA AND GVHD | PAPCIAK, SHARON M | 6d |
| 18506518 | ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF | JOHANSEN, PETER N. | 28d |
| 18118072 | METHODS AND COMPOSITIONS FOR DETECTING RISK OF CANCER RELAPSE | BURKHART, MICHAEL D | 41d |
| 17426728 | SENOLYTIC CAR-T CELLS TARGETING UPAR, A CELL SURFACE AND SECRETED SENESCENCE BIOMARKER | DIBRINO, MARIANNE | 79d |
| 18799294 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | DHAR, MATASHA | — |
| 18188795 | IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | ZHU, JIANJIAN | — |
| 17956957 | METHODS OF GENERATING MIDBRAIN DOPAMINE NEURONS, MIDBRAIN NEURONS AND USES THEREOF | JOHNSON, ALLISON MARIE | — |
| 17681113 | METHODS OF GENERATING AND ISOLATING MIDBRAIN DOPAMINE NEURONS | TRAN, KHOA NHAT | — |
| Art Unit | Apps |
|---|---|
| 1644 | 4 |
| 1632 | 3 |
| 1643 | 3 |
| 1638 | 2 |
| 1682 | 2 |
| 1641 | 2 |
| 1634 | 2 |
| 1642 | 2 |
| 1657 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18799294 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | DHAR, MATASHA | — | §112DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18606866 | INTESTINAL MICROBIOTA AND GVHD | PAPCIAK, SHARON M | 1657 | §103 | Final Rejection | 6d | Pending | Mar 15, 2024 |
| 18506518 | ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF | JOHANSEN, PETER N. | 1644 | §103 | Non-Final OA | 28d | Pending | Nov 10, 2023 |
| 18368647 | METHODS OF PERSONALIZED PRECONDITIONING FOR CELL THERAPY | DUNN, LINDSAY MICHELLE | 1644 | §103 | Non-Final OA | 26d | Pending | Sep 15, 2023 |
| 18188795 | IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | ZHU, JIANJIAN | 1631 | DP | Non-Final OA | — | Pending | Mar 23, 2023 |
| 18118072 | METHODS AND COMPOSITIONS FOR DETECTING RISK OF CANCER RELAPSE | BURKHART, MICHAEL D | 1638 | §112 | Non-Final OA | 41d | Pending | Mar 06, 2023 |
| 17956957 | METHODS OF GENERATING MIDBRAIN DOPAMINE NEURONS, MIDBRAIN NEURONS AND USES THEREOF | JOHNSON, ALLISON MARIE | 1638 | §112DP | Final Rejection | — | Pending | Sep 30, 2022 |
| 17890694 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK OF POOR CANCER SURVIVAL | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§102§112Other | Non-Final OA | 34d | Pending | Aug 18, 2022 |
| 17697044 | GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION | ANGELL, JON E | 1637 | §112 | Final Rejection | 156d overdue | Pending | Mar 17, 2022 |
| 17697028 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §101§103§112 | Non-Final OA | 91d overdue | Pending | Mar 17, 2022 |
| 17681113 | METHODS OF GENERATING AND ISOLATING MIDBRAIN DOPAMINE NEURONS | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17526812 | MESOTHELIN CARS AND USES THEREOF | DIBRINO, MARIANNE | 1641 | §103§112Other | Final Rejection | — | Pending | Nov 15, 2021 |
| 17405613 | COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY | GEORGE, DENNIS CHERIAN | 1644 | §103§112DP | Final Rejection | — | Pending | Aug 18, 2021 |
| 17400689 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | WU, JULIE ZHEN QIN | 1643 | §103 | Final Rejection | 33d | Pending | Aug 12, 2021 |
| 17319495 | STEM CELL-BASED MULTIPLEX METHODS AND COMPOSITIONS | TRAN, KHOA NHAT | 1632 | §101§103§112 | Final Rejection | — | Pending | May 13, 2021 |
| 17095216 | METHODS FOR IDENTIFYING ANTIGEN-SPECIFIC T CELL RECEPTORS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2020 |
| 16990185 | NON-HLA RESTRICTED T CELL RECEPTORS AND USES THEREOF | RIGA, MICHAEL ANGELO | 1634 | §103§112 | Non-Final OA | 4d overdue | Pending | Aug 11, 2020 |
| 18707578 | IL33 PROTEINS AND METHODS OF USE THEREOF | ABBAS, SYED JARAR | 1674 | §102 | Non-Final OA | — | Pending | May 04, 2024 |
| 18392127 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MOSELEY II, NELSON B | — | §103DP | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18501782 | A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY | BRISTOL, LYNN ANNE | 1643 | §102§112Other | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18250607 | PATIENT-SPECIFIC THERAPEUTIC PREDICTIONS THROUGH ANALYSIS OF FREE TEXT AND STRUCTURED PATIENT RECORDS | WASEEM, HUMA | 3686 | §101§103 | Final Rejection | — | Pending | Apr 26, 2023 |
| 18249914 | SYNTHETIC INTRONS FOR TARGETED GENE EXPRESSION | CANDELARIA, JULIANA IRENE | 1634 | §103§112 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18043527 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | DUFFY, BRADLEY | 1643 | §102 | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18007292 | COMPOSITIONS INCLUDING EX VIVO ARMED T CELLS WITH MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | MOSELEY II, NELSON B | 1642 | §103§112DP | Non-Final OA | — | Pending | Jan 27, 2023 |
| 17999786 | ANTI-GD2 SADA CONJUGATES AND USES THEREOF | LANDSMAN, ROBERT S | 1647 | §103Other | Non-Final OA | 14d | Pending | Nov 23, 2022 |
| 17914731 | SYSTEMS AND METHODS FOR DISTINGUISHING PATHOLOGICAL MUTATIONS FROM CLONAL HEMATOPOIETIC MUTATIONS IN PLASMA CELL-FREE DNA BY FRAGMENT SIZE ANALYSIS | BAILEY, STEVEN WILLIAM | 1687 | §101§103§112 | Non-Final OA | 15d | Pending | Sep 26, 2022 |
| 17911093 | DIGITAL PATHOLOGY RECORDS DATABASE MANAGEMENT | WORKU, SARON MATTHEWOS | 2408 | §103 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17794340 | INTRAOPERATIVE 2D/3D IMAGING PLATFORM | RAYMOND, KEITH MICHAEL | 3798 | §103§112 | Final Rejection | — | Pending | Jul 21, 2022 |
| 17766027 | SMALL MOLECULE INHIBITORS OF Id PROTEINS | TAO, BIN | 1625 | §102§103 | Non-Final OA | — | Pending | Apr 01, 2022 |
| 17626941 | METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY | LU, CHENG | 1642 | §103§112 | Non-Final OA | — | Pending | Jan 13, 2022 |
| 17549811 | METHODS AND COMPOSITIONS FOR REDUCING VANCOMYCIN-RESISTANT ENTEROCOCCI INFECTION OR COLONIZATION | MOAZZAMI, NAGHMEH NINA | 1652 | §103 | Final Rejection | — | Pending | Dec 13, 2021 |
| 17611805 | METHODS FOR PREDICTING RESPONSIVENESS OF CANCER TO FERROPTOSIS-INDUCING THERAPIES | BAUSCH, SARAE L | 1699 | §103§112 | Final Rejection | — | Pending | Nov 16, 2021 |
| 17594271 | MULTI-VALENT IMMUNOTHERAPY COMPOSITION AND METHODS OF USE FOR TREATING WT1-POSITIVE CANCERS | DRISCOLL, MAUREEN VARINA | 1644 | §103§112 | Non-Final OA | — | Pending | Oct 08, 2021 |
| 17426728 | SENOLYTIC CAR-T CELLS TARGETING UPAR, A CELL SURFACE AND SECRETED SENESCENCE BIOMARKER | DIBRINO, MARIANNE | 1641 | §102 | Non-Final OA | 79d | Pending | Jul 29, 2021 |
| 17196631 | METHODS AND COMPOSITIONS FOR DETECTION OF HPV DNA AND DIAGNOSIS AND MONITORING OF HPV-ASSOCIATED CANCERS | HANEY, AMANDA MARIE | 1682 | §103 | Non-Final OA | 7d | Pending | Mar 09, 2021 |
| 17259800 | METHODS OF USING PHARMACOLOGIC INHIBITORS OF TYPE 2 CYTOKINE SIGNALING TO TREAT OR PREVENT PANCREATIC CANCER | BERHANE, SELAM | 1675 | §103 | Non-Final OA | 89d overdue | Pending | Jan 12, 2021 |
| 17047621 | SYSTEMS AND METHODS FOR DETECTING CANCER VIA cfDNA SCREENING | CHUNDURU, SURYAPRABHA | 1681 | §101§103 | Non-Final OA | 17d overdue | Pending | Oct 14, 2020 |
| 16979396 | METHODS OF SELECTING T CELL LINE FOR ADOPTIVE CELLULAR THERAPY | CHASE, CAROL ANN | 1646 | §112Other | Final Rejection | 41d | Pending | Sep 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial